The Alliance is a community dedicated to connecting healthcare education professionals to promote best practices that improve patient care. To help achieve this, we collect information on research proposals and grants offered through other healthcare-related organizations. If your company is interested in posting a request for grant applications, please contact the Alliance Business Office at acehp@acehp.org.
Amicus Therapeutics
Amicus Therapeutics is committed to supporting high quality independent medical education (IME) that narrows unmet educational needs and improves healthcare provider knowledge, competence, and clinical practice. IME supported by Amicus is intended to ultimately improve the outcomes of patients with rare and orphan diseases.
Please visit our website at Amicus Global Medical Affairs to learn more about current opportunities.
Astellas
Click here to view open CGAs. If you have any questions please contact Astellas IME/IPE at grants@astellas.com.
AstraZeneca
To view open RFPs and complete details regarding grant submission, please visit AstraZeneca IME website: www.astrazeneca-us.com. Please submit any questions regarding RFPs to grants@astrazeneca.com
Biogen
Biogen is committed to advancing disease education and improving patient care through consideration of grant proposals for independent medical education activities. For information on Biogen's submission process and areas of interest, please visit Biogen's Grants & Giving website.
Bristol-Myers Squibb
Bristol-Myers Squibb accepts funding requests within the following therapeutic areas of interest. As areas of interest and funding consideration may change periodically, please consult this website frequently. Please note that international funding opportunities may differ.
- Cardiovascular
- Immunoscience
- Oncology
- Virology
- Genetically Defined / Rare Diseases
View Request for Proposals / for Education
Daiichi-Sankyo
At the current time this package, issued March 29, 2021, outlines the only Daiichi Sankyo-issued RFPs for Fiscal Year 2021.
Daiichi Sankyo believes education is a source to accelerating best, personalized evidence into clinical practice for the best interest of patient care. Our commitment is to make grant funding available for independent, fair, balanced, and scientifically accurate medical education initiatives that receive no influence from our organization in either submission, design, or implementation. Grant conduct is required to comply with all expected regulatory requirements. At times, Daiichi Sankyo accepts grant submissions that are in response to call for grant applications, better known as Request(s) for Proposals (RFPs). When published, RFPs will provide details regarding externally referenced educational, clinical, practical, and/or research gaps in specific therapeutic focus areas, along with referenced-driven recommendations for learning audiences, and timeline submission requirements. We invite eligible organizations to log into the grant portal for information on currently available RFPs. Daiichi Sankyo reserves the right and may publish additional RFPs as the year progresses.
- Two (2) General Call for Grants: HER2 positive Tumors; and Hematology
- Four (4) Timed RFPs: Cancer Therapy Induced Interstitial Lung Disease (ILD) and Pneumonitis; HER3 Expression in Advanced Solid Tumors and HER3 Expression in EGFRm NSCLC; TROP2 ADCs in Advanced/Metastatic NSCLC; and Tenosynovial Giant Cell Tumor (TGCT)
Please submit any questions regarding RFPs to OGE-CME@dsi.com.
Eli Lilly and Company
Therapeutic Area: Oncology - Colorectal Cancer
Submission Deadline: February 18, 2022
Please use the following budget template.
View Eli Lilly and Company RFP.
To view other current opportunities visit Lilly Grant Office portal.
Emergent BioSolutions
At Emergent, our mission is to protect and enhance life and we recognize the value that third-party independent medical education can bring to fulfilling this mission. Emergent is committed to supporting third-party continuing medical education that is high-quality, un-biased, and evidence-based to further expand the scientific and clinical knowledge of the disease states and therapeutic areas in which we are focused. Our current areas of focus include:
- Travel Health
- Emerging Infectious Diseases
- Opioid Use and Overdose
We are currently accepting educational grant requests (up to $100,000) in the above areas of focus now through January 15, 2022. Decisions on grants submitted by January 15, 2022 will be communicated by March 15, 2022. For more information or to request an IME Request Form to submit a grant request, please contact MedicalGrants@ebsi.com.
Genentech
Genentech is seeking to support learning initiatives that demonstrate a strategy that evolves knowledge-based medical education into a "healthcare Improvement" initiative that accelerates the awareness and application of evidence-based medicine, resulting in appropriate care for patients and relevant, measurable, clinical outcomes.
To view opportunities and complete details regarding grant submission, please visit Genentech.
Grail
GRAIL is committed to funding innovative and impactful education to support practicing healthcare professionals and the communities of care that they manage within our areas of interest. GRAIL is open to the receipt of unsolicited Independent Medical Education grants. To inquire further please reach out to meded@grail.com.
To apply for funding, and for more information regarding our areas of interest, including example educational objectives, please visit www.grail.com/meded.
Illumina, Inc.
Illumina is committed to the advancement of medicine and improvement of patient care by increasing awareness of the utility of genomics in medicine.
Please visit our website for additional information about our education and research endeavors, and to access optional templates that can be used for submission.
Indivior
Indivior supports independent medical education activities that provide for an increased understanding of scientific, clinical, or healthcare issues related to the company's therapeutic areas of interest.
Therapeutic areas of interest:
- Opioid Use Disorder
- Schizophrenia
To view open RFPs and complete details regarding grant submission, please visit the following site on a regular basis: grants.indivior.com
Insmed Incorporated
Insmed has funding to support independent accredited education intended to improve clinician knowledge, competence, and performance in the diagnosis and treatment of patients with Nontuberculous Mycobacterial (NTM) Lung Disease. Please refer to https://insmed.com/culture/responsibility/grants-funding/ for grant submission requirements. For additional questions about the CGA process please contact Insmed Medical Education at grants@insmed.com. Grant submissions should align to the specifications in the downloadable CGA.
Therapeutic Areas: Pulmonology/Infectious Disease
Non-Cystic Fibrosis Nontuberculous Mycobacterial Lung Disease (NTM-LD)
Submission Deadline: February 28, 2022
View INSMED Call for Medical Education Grant Applications (CGA)
Jazz Pharmaceuticals
Jazz Pharmaceuticals is committed to improving patient outcomes and providing support in compliance with local regulations. The Jazz grant management system is currently accepting requests for medical education meetings, conferences, or symposia; medical center grand rounds lectures; fellowships; enduring medical education activities; and similar educational activities. In Europe and Rest of World (EU/RoW) the system is also accepting requests for goods (such as books, printing, materials, equipment) and services (such as administrative support, personnel, and tools).
Therapeutic areas of interest:
- Neuroscience
- Hematology/Oncology
View Request for Application (RFA)
Any questions can be directed to Jazz's Medical Education Grants email address (mededgrant@jazzpharma.com). Please visit our website for additional information.
Medicare Access and CHIP Reauthorization Act of 2015 (MACRA)
The Centers for Medicare & Medicaid Services (CMS) recognizes the benefits of measure development by external stakeholders with specific knowledge of clinician and patient perspectives and needs, such as clinical specialty societies, clinical professional organizations, patient advocacy organizations, educational institutions, independent research organizations, health systems, and other entities.
On March 2, 2018, CMS published the "Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) Funding Opportunity: Measure Development for the Quality Payment Program" on Grants.gov. The purpose of this Funding Opportunity is to provide technical and funding assistance in the form of cooperative agreements to entities to develop, improve, update, or expand quality measures for use in the Quality Payment Program (QPP).
For more information and to see the 'Medicare Access and CHIP Reauthorization Act of 2015 (MACRA) Funding Opportunity: Measure Development for the Quality Payment Program' search by the title or the Catalog of Federal Domestic Assistance (CFDA) number, 93.986 on Grants.gov.
Merck & Co, Inc.
Merck supports quality independent medical education (IME) for healthcare professionals designed to help improve patient health outcomes, across a variety of scientific/therapeutic areas. Please review request(s) for proposals for IME, and submit all related requests through our grant portal: www.msdgrant.com.
Novartis
To view open Request for Proposals (RFPs) and for complete details regarding grant/sponsorship submissions, please visit Novartis. If you have any questions, please contact the Novartis Oncology Office of Grants and Education at onc.grants@novartis.com.
Novo Nordisk Inc.
Novo Nordisk is committed to supporting independent medical education (IME) programs that meet the educational needs of health care professionals (HCPs), patients and the community in ways that measurably grow their knowledge and skills to optimize care.
Please visit our website and log in to apply for educational grant funding, access the IME Funding Document that provides information about educational priorities and available funding across our therapeutic areas of interest, and view open Request for Proposals (RFPs)/Call for Concept Proposals (CCPs). Email questions to grantsoffice@novonordisk.com.
Pfizer Independent Grants for Learning & Change (IGLC)
The mission of Pfizer Independent Grants for Learning & Change is to partner with the global healthcare community to improve patient outcomes in areas of mutual interest through support of measurable learning and change strategies. The Joint Commission is an independent, not-for-profit organization that accredits and certifies nearly 21,000 health care organizations and programs in the United States.
To view open RFPs and complete details, please visit this webpage.
Regeneron Pharmaceuticals
The Regeneron and Sanofi Genzyme Alliance is now accepting applications for support of independent medical education initiatives developed to close healthcare gaps associated with eosinophilic esophagitis (EoE) in the specialty audience of gastroenterology, allergy, and immunology.
Education is needed to improve knowledge of disease pathophysiology, recognition, chronicity and progression; limitations of current standards of care; and new clinical trial data for emerging therapies. To this end, the Sanofi Genzyme Alliance invites applications for high-quality educational initiatives designed for impactful learner engagement to address these needs. Please refer to the Request for Proposal for further details.
Sanofi
To view and respond to open RFPs, please go to: https://sgrants.envisionpharma.com/vt_sgrants/
Seagen
Seagen is committed to supporting innovative independent medical education (IME) for healthcare professionals and patients. We provide grants in support of accredited and unaccredited medical education programs that address unmet medical needs, foster clinical excellence, and improve health outcomes. At the moment, we seek to support medical and patient education in the following therapeutic areas:
• Breast cancer
• Cervical cancer
• Colorectal cancer
• Hodgkin lymphoma (United States and Canada only)
• Non-Hodgkin lymphoma (United States and Canada only)
• Urothelial carcinoma
Click here to apply.
Other grant opportunities - Investigator Sponsored Reseach: Health Outcomes
Shionogi Inc.
Shionogi accepts funding requests within the following therapeutic areas of interest.
- Gram-negative multidrug-resistant infectious disease (ID)
- Thrombocytopenia associated with chronic liver disease (CLD)
- Opioid-induced Constipation (OIC)
The call for grants (CFG) opportunities will change on a quarterly basis. Please consult our website to identify current opportunities.
Takeda
Takeda supports the education of Healthcare professionals relating to its therapeutic areas of interest through its grants program. Takeda is open to unsolicited grant requests, submitted at anytime during the year. Takeda also will post Call for Grant Applications (CGA's), from time to time throughout the year. You can find the Takeda medical education grants portal here: www.tsupportportal.com. For any questions regarding Takeda medical education grants, please email: IndependentMedicalEducation.TakedaSupport@takeda.com
TRC Healthcare
TRC Healthcare (TRC), the creators of Pharmacist's Letter, is committed to helping clinicians and healthcare professionals make safe, effective, and efficient medication decisions.
To learn more about TRC and view open RFPs, please visit TRC Healthcare.
Travere Therapeutics
Travere Therapeutics is a biopharmaceutical company whose mission is to identify, develop and deliver life-changing therapies to people living with rare diseases. To view open RFP, click here.
To learn more, please visit Travere Therapeutics.
VBI Vaccines Inc
VBI Vaccines Inc. (VBI) is a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease. Aligned with our mission to target and overcome significant infectious diseases, we are committed to supporting the healthcare community's ability to improve patient outcomes related to the prevention of hepatitis B.
Please submit any questions to grants@vbivaccines.com.